A Moll

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Adriano Lazzarin, Thomas Campbell, Bonaventura Clotet et al. · The Lancet · 2007 · 392 citations

Medicine, Infectious Diseases, Pharmacology +12

A highly virulent variant of HIV-1 circulating in the Netherlands

Chris Wymant, Daniela Bezemer, François Blanquart et al. · Science · 2022 · 75 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +14

Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (<scp>DAA</scp>)‐based hepatitis C virus (<scp>HCV</scp>) therapy from the National German <scp>HCV</scp> registry: does <scp>HIV</scp> coinfection impair the response to <scp>DAA</scp> combination therapy?

Jenny Bischoff, Stefan Mauss, C Cordes et al. · HIV Medicine · 2018 · 44 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Considerable Under-Treatment of Chronic HCV Infection in HIV Patients despite Acceptable Sustained Virological Response Rates in a Real-Life Setting

Thomas Reiberger, Martin Obermeier, B.A. Payer et al. · Antiviral Therapy · 2011 · 34 citations

Pharmacy, Infectious Diseases, Microbiology +12

Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German ‘WIP’ cohort

Uta Naumann, A Moll, D. Schleehauf et al. · International Journal of STD & AIDS · 2016 · 20 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17